03/2021: Russian developer Mabscale in-licensed UGA Biopharma´s biosimilar cell lines

UGA has out-licensed two of its innovative ready-to-use biosimilar cell lines to Russia-based biosimilar developer Mabscale, who will now conduct GMP manufacturing and clinical studies to obtain marketing authorizations for the Russian market.

The cell lines in-licensed by Mabscale are among a wide range of ready-to-use biosimilar cell lines for GMP manufacturing developed by UGA. These in-house developed CHO-based cell lines stably express different biosimilar molecules to make them instantly available for in-licensing. Client advantages include direct access to proven cell lines that come bundled with all development data, including high titer and assured quality attributes.

For more information, please click here.




Contact

UGA Biopharma GmbH
Neuendorfstraße 20a
16761 Hennigsdorf
Germany
E-mail:  info@ugabiopharma.com This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: +49(0)3302 / 2024900